Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
about
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an UpdateTranscription factor GATA-1 and Down syndrome leukemogenesisTreatment and prognostic impact of transient leukemia in neonates with Down syndromeHematological disorders and leukemia in children with Down syndrome.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologyAppraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature ReviewPossibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.Optimizing therapy for myeloid disorders of Down syndrome.Treatment of childhood acute myeloid leukemia.Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Normal and malignant megakaryopoiesis.Trisomy correction in Down syndrome induced pluripotent stem cells.Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinomaCardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeThe role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapyRUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.Malignancy in children with trisomy 21.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.Unique clinical and biological features of leukemia in Down syndrome children.Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer.Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study.Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis.Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group.Acute leukemia in children with Down syndrome.Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study.AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias.Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.
P2860
Q28079980-6E28E228-1D57-407B-B840-8BA47DC517F8Q28251869-8850F5A7-81A4-47FA-B887-0CB215F76198Q33378192-ADCF3267-E3BA-47B0-B9A5-3B48286F114AQ33398426-216BEAE0-AA31-4DE1-862B-F84BA6B1A75AQ33698398-DDF184F0-ABE0-4343-9DE9-9741CEE404EAQ33952766-42D4C2A4-4789-41A1-BEDD-EABB8E2B2883Q34611232-EEC84B51-F3EC-4FC1-8042-9894C1CC6A62Q35635570-93FED596-8BAE-4012-8099-4012F75B8913Q35888110-A0B3E027-337B-4FF9-91BF-989A3C19470DQ35921471-8F4D0973-8C51-4300-BE9A-6007005AB34FQ36262215-7FBDE1C6-19BD-4E75-AF35-73D61BF30B28Q36284532-FF8CEED0-FCD8-4F65-9DB6-33D2927480F7Q36334267-1A7647EF-1D9D-4FF6-B6AD-4F6C5E6FD714Q36828315-42E83D11-1ADF-4D06-81CD-4BF66509904FQ36909019-F5E913F4-58D7-49F7-9A35-8CB0EA1B6597Q36995232-09518A08-5D83-484E-B237-C733382C89A3Q37000896-43B44283-57CA-4B60-AD08-959BF512DBF9Q37003403-49AFC272-E2F5-4F74-8753-917DF4588221Q37059586-7B06A420-4C27-4B78-8AEC-8276B45371AFQ37087261-1AF7D1F8-71D3-4565-A556-A74D4BFC6732Q37142140-A02E66D0-67C5-4ED5-B79F-C88FFE412A13Q37259709-7CECD8DA-E78B-4751-927E-AA574B1FE800Q37372829-C17CD71E-C346-4582-BC36-B965EFB8286CQ37379570-A325D8A5-4537-42BA-A806-427EBBC7B902Q37429718-428F1B3A-A74D-4937-9936-C1DC0A3494C7Q37552027-56EFBDC3-97A8-4531-AC49-9DA97B7F40DAQ37810271-6DADDAA3-56A7-4663-A7A7-9627DE0E4600Q38767064-B835F705-6C20-44DE-8E0B-2989E3DA3EBBQ39000725-467057CF-9294-4E51-BF41-40F8C36E144FQ39822035-7F548A91-E8DD-4475-8746-0F59043B40E1Q39873557-8485CEF7-24C8-422B-9C36-836C1E4B9FA0Q40176569-A1AA2A52-D2D6-470E-BB0D-E018BD68E489Q40182103-48C0B368-1B0D-401F-9F42-5E96178794F6Q40354450-F98B47D0-883D-47E4-8706-93E7D1F0B56BQ42012900-011FF0FB-F14B-4335-9CBC-5E1F62DFB3F7Q42739970-E5DD7549-256E-4756-A382-087F050B2BF4Q45388674-4F0F1A63-B74E-452A-A47A-0A3D3A2B1B3DQ46513852-B1256BC9-DF6D-4629-826F-34A77C22E55CQ53086558-879E2F92-A369-40DA-A165-DB2036EC9590Q53270825-CA13432B-CE11-446B-81C9-3D3CBD97900D
P2860
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Different drug sensitivity pro ...... ith and without Down syndrome.
@en
Different drug sensitivity pro ...... ith and without Down syndrome.
@nl
type
label
Different drug sensitivity pro ...... ith and without Down syndrome.
@en
Different drug sensitivity pro ...... ith and without Down syndrome.
@nl
prefLabel
Different drug sensitivity pro ...... ith and without Down syndrome.
@en
Different drug sensitivity pro ...... ith and without Down syndrome.
@nl
P2093
P356
P1433
P1476
Different drug sensitivity pro ...... ith and without Down syndrome.
@en
P2093
Anjo J P Veerman
Christian M Zwaan
Christina H van Zantwijk
Dieuwke R Huismans
Esther de Vries
Gerrit Jansen
Gertjan J L Kaspers
Godefridus J Peters
Gritta E Janka-Schaub
Karel Hählen
P304
P356
10.1182/BLOOD.V99.1.245
P407
P50
P577
2002-01-01T00:00:00Z